Multiple hats

About Multiple hats

Multiple Hats is a STEM career podcast for professionals who want more than the 9–5. Hear real stories of STEM professionals reinventing their careers — from scientists turned founders to biotech consultants and entrepreneurs. Hosted by Angelique Greco, a biotech and health-tech expert with 15+ years across the drug development lifecycle, this show explores how STEM careers can evolve into entrepreneurship, thought leadership, and portfolio work that truly matters. Through in-depth conversations with entrepreneurial STEM professionals, you’ll discover: Where a STEM degree can take you (career possibilities are infinite). How to embrace your unique “patchwork” of skills and experiences. Practical tactics to reinvent, transition, or leap into new opportunities. Mindset shifts from “Can I?” to “Here’s how!” You will hear: Indepth interview to hear the whole story Quick wins episode with key takeaways and actionable insights for you Practical tips to help you change your self limiting mindsets and grow further For who: Scientists, PhDs, engineers, clinicians, biotech consultants, tech pros including women balancing STEM careers with motherhood while fighting stereotypes. Why listen: Representation and role modelling matter. Bold and brave STEM professionals share how they carved their own paths — so you can too. 🎙 New episodes weekly. Follow now to reinvent your STEM career and design work on your own terms. STEMM = Science Technology Engineering Mathematics Medicine Visit my website https://angeliquegreco.com.au/ (https://angeliquegreco.com.au/) for short bite insights and on how to start crafting your message to set you on track for the career your want. bumper-verify-280239a7 Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.

Publisher

Angelique Greco | Biotech & Health-Tech Expert | STEM Thought Leadership Coach

Category

business · business · science

Language

en

Explicit

No

First episode

5 Mar 2023

Latest episode

26 Oct 2026

Latest episodes

66 episodes in the feed.

1. 

   26 Oct 2026

   Can You Make Mice Smarter? Turning Wild Science Into Medicine with early biotech industry feedback with Prof Greg Neely

   Can you make mice smarter? Professor Greg Neely did. But turning fascinating science into a medicine means answering much harder questions about safety, dosing, translation to humans and where to start clinically. In this episode, we explore Greg’s work using mRNA and lipid nanoparticles to deliver proteins through the nose and into the brain, and what happened when biotech and drug development experts stress-tested his development plan for the first time. Their questions changed his roadmap. Greg’s team at the University of Sydney started by delivering oxytocin before moving to BDNF, a protein involved in brain function that normally cannot cross the blood-brain barrier. The early results showed they could get BDNF into the brain and improve cognition in animals. Then came the commercialisation questions. Will intranasal delivery translate from mice to humans? How do you control the dose? How do you demonstrate target engagement? What are the safety risks? And even if the technology works, is Alzheimer’s really the right disease to tackle first? For a scientist moving towards entrepreneurship, these are very different questions from those asked in an academic lab. After the Drug Discovery Forum, Greg began looking more seriously at Rett syndrome as a possible first clinical indication, considered new validation experiments, refined his pitch and took that stronger story to BIO in San Diego. It’s a real-life example of how bringing biotech expertise into an academic project early can expose blind spots while there’s still time to change the plan. In this episode: Using mRNA and lipid nanoparticles to deliver proteins to the brain Moving from scientific discovery towards a potential medicine What changes when academic science meets biotech expertise Translating animal data to humans Dose, safety and target engagement in early drug development Why choosing the right first clinical indication matters Alzheimer’s disease, Rett syndrome and other potential applications How industry feedback changed Greg’s development roadmap What scientist entrepreneurs can learn from putting their science in front of industry early This episode is Part 4 of a six-part series exploring the path from academic research to biotech and drug development, based on conversations from the 2026 Drug Discovery Forum in Sydney. Across the series, scientists, biotech entrepreneurs, industry experts and technology transfer professionals explore what it takes to move promising research beyond the lab and towards patients. Want to craft a career story that opens doors? I help STEMM professionals speak with clarity, confidence, and purpose and show up as thought leaders —so the right opportunities find you. 📬 Let’s connect: angeliquegreco.com.au (https://angeliquegreco.com.au) | LinkedIn (https://linkedin.com/in/angelique-greco) ⭐️ Help More People Reinvent Their Careers If you enjoyed this episode, please: ✅ Leave a quick ⭐️⭐️⭐️⭐️⭐️ review on Apple Podcasts or Spotify (https://podcasts.apple.com/au/podcast/multiple-hats/id1666244822) 🙏 ♻️ Share it with a friend who's questioning their path in STEM Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.

2. 

   12 Oct 2026

   Scientist Entrepreneur: How to Assess the Commercial Potential of Your Research with Dr Laura Issa

   You have promising science. But is there actually a commercial opportunity behind it? And if you’re considering moving from scientist to entrepreneur, how do you know whether your research has the ingredients for a biotech company? Dr Laura Issa has spent years evaluating science through an industry and business development lens. She is the founder of Bespoke Genetic Medicines and co-founder of Facio Biotech, with experience across pharma, biotech, research commercialisation and rare disease. In this conversation, Laura gives us a practical framework for assessing the commercial potential of scientific research. We start with what she looks for when academics pitch their research to industry. Good science alone isn’t enough. Researchers need to understand what makes their approach meaningfully different, the competitive landscape, their intellectual property strategy and the evidence required to support their claims. We also discuss when to seek industry feedback, why talking to patients, clinicians and payers early can change your research strategy, and when market research should begin. Spoiler: probably earlier than many scientists think. Then we tackle the biotech spin-out question. Laura shares five factors she considers when assessing whether academic research could become a viable biotech company, including unmet need, intellectual property, capital requirements, stage of development and the people needed to take it forward. And importantly, starting a company isn’t automatically the answer. Sometimes licensing, partnering with industry or remaining in academia longer is the better development strategy. We also explore why Laura remains optimistic about drug development in neurology despite its history of clinical failures, including the growing role of human-derived models, biomarkers, genomic and clinical datasets, and new approaches to generating evidence. Finally, we move to a very different commercialisation problem: ultra-rare genetic disease. Laura explains why conventional drug development economics can break down when a potential treatment may serve fewer than 100 people, and why these therapies may require completely different funding and development models. In this episode: How to assess the commercial potential of academic research What industry looks for when scientists pitch a biotech opportunity Differentiation, competitive landscape and IP strategy When scientists should seek feedback from industry Why patient, clinician and payer insights matter early Five factors to consider before creating a biotech spin-out When licensing or partnering may make more sense than starting a company Balancing patents, publication and academic incentives Why drug development in neurology may be entering a different era The challenge of developing treatments for ultra-rare genetic diseases Why patient need and commercial viability are not always the same thing This episode is Part 3 of a six-part series exploring the path from academic research to biotech and drug development, based on conversations from the 2026 Drug Discovery Forum in Sydney. Across the series, scientists, biotech entrepreneurs, industry experts and technology transfer professionals unpack what it takes to move promising research beyond the lab and towards patients. Want to craft a career story that opens doors? I help STEMM professionals speak with clarity, confidence, and purpose and show up as thought leaders —so the right opportunities find you. 📬 Let’s connect: angeliquegreco.com.au (https://angeliquegreco.com.au) | LinkedIn (https://linkedin.com/in/angelique-greco) ⭐️ Help More People Reinvent Their Careers If you enjoyed this episode, please: ✅ Leave a quick ⭐️⭐️⭐️⭐️⭐️ review on Apple Podcasts or Spotify (https://podcasts.apple.com/au/podcast/multiple-hats/id1666244822) 🙏 ♻️ Share it with a friend who's questioning their path in STEM Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.

3. 

   28 Sept 2026

   From Scientist to Biotech: How Industry Feedback from Biotech Experts Changes Your Drug Development Roadmap -

   What happens when scientists stop presenting their research to other scientists and put it in front of biotech and drug development experts instead? The questions change. Suddenly it isn’t only, “Does the science work?” It’s also: Who is the patient? What is the indication? What evidence do you need next? What could stop this programme? Who needs to partner with you? And what would a credible path to the clinic actually look like? In this episode, Professor Greg Neely and Dr Jean Bertoldo share what happened when they pitched their research to industry experts at the 2026 Drug Discovery Forum ( ARCS conference 2026) Their projects are at very different stages. Prof Greg Neely is combining established biology and delivery technologies to explore new neurological applications. Dr. Jean Bertoldo is working much earlier, building evidence around new biology in childhood brain cancer. Both walked away with questions that changed how they thought about their drug development roadmap. We also speak with Dr Gorjana Mitic about technology transfer and the role tech transfer professionals can play in helping scientists move promising academic research towards licensing, partnering or a biotech spin-out. Gorjana takes us behind the scenes of a tech transfer office, including why promising projects can get stuck, what technology transfer teams actually assess, and what scientists can do to make their research easier to champion. You’ll hear about: How industry feedback can expose blind spots in a drug development plan Moving from an interesting scientific project to a credible path towards the clinic How scientists can think about indication selection and development strategy Why biotech development requires partners and capabilities beyond the academic lab What technology transfer offices actually do Why academics and tech transfer teams sometimes clash What makes academic research easier for a tech transfer team to champion How scientists can prepare for commercialisation, licensing or a biotech spin-out This episode is Part 2 of a six-part series exploring the path from academic research to biotech and drug development, based on conversations from the 2026 Drug Discovery Forum in Sydney. Across the series, we hear from scientists, biotech entrepreneurs, technology transfer professionals and industry experts about the decisions, evidence and people needed to give promising research its best chance of reaching patients. Want to craft a career story that opens doors? I help STEMM professionals speak with clarity, confidence, and purpose and show up as thought leaders —so the right opportunities find you. 📬 Let’s connect: angeliquegreco.com.au (https://angeliquegreco.com.au) | LinkedIn (https://linkedin.com/in/angelique-greco) ⭐️ Help More People Reinvent Their Careers If you enjoyed this episode, please: ✅ Leave a quick ⭐️⭐️⭐️⭐️⭐️ review on Apple Podcasts or Spotify (https://podcasts.apple.com/au/podcast/multiple-hats/id1666244822) 🙏 ♻️ Share it with a friend who's questioning their path in STEM Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Spotify

5.0 / 5

7 ratings

Podcast Authority Score: 24 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

24

Social presence

0

YouTube

0

Engagement

60

Contact Multiple hats

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.